Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;62(5):6283-6307.
doi: 10.1007/s12035-024-04672-w. Epub 2025 Jan 7.

Cholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets

Ning-Qi Wang  1   2 , Pei-Xiang Sun  1   2 , Qi-Qi Shen  1   2 , Meng-Yan Deng  3
Affiliations
Review

Cholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets

Ning-Qi Wang et al. Mol Neurobiol. 2025 May.

Abstract

The brain is the organ with the highest cholesterol content in the body. Cholesterol in the brain plays a crucial role in maintaining the integrity of synapses and myelin sheaths to ensure normal brain function. Disruptions in cholesterol metabolism are closely associated with various central nervous system (CNS) diseases, including Alzheimer's disease (AD), Huntington's disease (HD), and multiple sclerosis (MS). In this review, we explore the synthesis, regulation, transport, and functional roles of cholesterol in the CNS. We discuss in detail the associations between cholesterol homeostasis imbalance and CNS diseases including AD, HD, and MS, highlighting the significant role of cholesterol metabolism abnormalities in the development of these diseases. Sterol regulatory element binding protein-2 (SREBP2) and liver X receptor (LXR) are two critical transcription factors that play central roles in cholesterol synthesis and reverse transport, respectively. Their cooperative interaction finely tunes the balance of brain cholesterol metabolism, presenting potential therapeutic value for preventing and treating CNS diseases. We particularly emphasize the alterations in SREBP2 and LXR under pathological conditions and their impacts on disease progression. This review summarizes current therapeutic agents targeting these two pathways, with the hope of broadening the perspectives of CNS drug developers and encouraging further study into SREBP2 and LXR-related therapies for CNS diseases.

Keywords: AD; Cholesterol homeostasis; HD; LXR; MS; SREBP2.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

References

    1. Björkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 806–815. https://doi.org/10.1161/01.ATV.0000120374.59826.1b
    1. Zhang J, Liu Q (2015) Cholesterol metabolism and homeostasis in the brain. Protein Cell 254–264. https://doi.org/10.1007/s13238-014-0131-3
    1. Genaro-Mattos TC, Anderson A, Allen LB, Korade Z, Mirnics K (2019) Cholesterol biosynthesis and uptake in developing neurons. ACS Chem Neurosci 3671–3681. https://doi.org/10.1021/acschemneuro.9b00248
    1. Liu Q, Trotter J, Zhang J, Peters MM, Cheng H, Bao J et al (2010) Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci 17068–17078. https://doi.org/10.1523/jneurosci.4067-10.2010
    1. Hannah MJ, Schmidt AA, Huttner WB (1999) Synaptic vesicle biogenesis. Annu Rev Cell Dev Biol 733–798. https://doi.org/10.1146/annurev.cellbio.15.1.733

MeSH terms

Substances

LinkOut - more resources